Regeneron Pharmaceuticals has launched a $250 million all-cash buyout offer for Checkmate Pharmaceuticals, valuing shares at $10.50 each and representing a substantial 332% premium over Checkmate's recent closing price. This acquisition is poised to enhance Regeneron's immuno-oncology portfolio, reflecting its commitment to leadership in biotechnology. The deal is anticipated to close by mid-2022, although Regeneron has acknowledged potential risks associated with expected benefits and managing net product sales in the future.
“Regeneron · closed at · price · $706.11”
“Shares of Regeneron · are doing · just fine”
“Regeneron Pharmaceuticals · made a buyout offer of · $250 million · all-cash”
“Regeneron Pharmaceuticals' tender offer · represents · a whopping 332% premium · relative to Checkpoint Pharmaceuticals' closing price Monday afternoon”
“Regeneron's tender offer · is at · $10.50 per share”
“Regeneron Pharmaceuticals, Inc. · extended review of · biologics license application for REGEN-COV · by three months”
“Regeneron Pharmaceuticals, Inc. · announced acquisition of · Checkmate Pharmaceuticals, Inc. · for $10.50 per share or $250 million”
“Regeneron Pharmaceuticals, Inc. · will acquire · Checkmate Pharmaceuticals, Inc. · $250 million”
“Regeneron · has two key growth drivers · Eylea and Dupixent · true”
“Regeneron has a collaboration agreement with Bayer · for · Eylea · true”
“Regeneron records its share of profits/losses · in connection with · international sales of Eylea · true”
“Regeneron currently carries · a Zacks Rank · #3 (Hold) · true”
